Wednesday August 12th 2020

Tags

Category

BISC Global is pleased to announce the opening of a new branch in Basel, Switzerland. The new Basel location complements the global presence with its current offices in Belgium, and USA (Boston and San Francisco).

“We are thrilled to be expanding our footprint into the vibrant research community of Basel” said Maarten Braspenning, CEO of BISC Global. “As a bioinformatics, statistics and machine learning consulting company with a global view and local approach, we believe Switzerland is a key location for the next step in our company’s growth. We look forward to supporting the local pharma and biotech companies, as well as the research institutes and universities that call Switzerland home.”

As the go-to bioinformatics consulting company, BISC Global will offer high quality services for data-analysis, visualization, interpretation and storage. Dr. Remco Foppen will be leading the effort to help the Swiss research community to make the most of their data.

“I am excited to support the Swiss research community with varied bioinformatic tools, and Swiss bioinformaticians with a career at BISC Global” said Remco Foppen, Business Manager Switzerland at BISC Global.

Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm supporting world’s leading pharmaceutical and biotech companies. Through our offices in Ghent, Belgium; Basel, Switzerland; Boston, MA; and San Francisco, CA; BISC Global provides data-analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. By leveraging our global workforce of expert consultants, we support analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modelling, signal-to-noise enhancement, and independent data cross validation).